Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

BACKGROUND: Ruxolitinib improves splenomegaly and symptoms in patients with intermediate-2 or high-risk myelofibrosis; however, nearly half develop grade 3/4 anemia and/or thrombocytopenia, necessitating dose reductions and/or transfusions. We report findings from an open-label phase 2 study explori...

Descripción completa

Detalles Bibliográficos
Autores principales: Talpaz, Moshe, Erickson-Viitanen, Susan, Hou, Kevin, Hamburg, Solomon, Baer, Maria R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081850/
https://www.ncbi.nlm.nih.gov/pubmed/30086777
http://dx.doi.org/10.1186/s13045-018-0642-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081850/
https://www.ncbi.nlm.nih.gov/pubmed/30086777
http://dx.doi.org/10.1186/s13045-018-0642-0

Ejemplares similares